share_log

Tracon Pharmaceuticals | EFFECT: Others

Tracon Pharmaceuticals | EFFECT: Others

Tracon Pharmaceuticals | EFFECT:其他
美股SEC公告 ·  11/04 06:04

Moomoo AI 已提取核心訊息

Tracon Pharmaceuticals, Inc. has received a Notice of Effectiveness from the United States Securities and Exchange Commission (SEC) on November 1, 2024. The notice indicates that the company's submission, identified by Accession Number 0000950170-24-119598 and submission type POS AM, has been officially accepted by the SEC. The filing, under File Number 333-234651, marks a significant regulatory milestone for Tracon Pharmaceuticals.
Tracon Pharmaceuticals, Inc. has received a Notice of Effectiveness from the United States Securities and Exchange Commission (SEC) on November 1, 2024. The notice indicates that the company's submission, identified by Accession Number 0000950170-24-119598 and submission type POS AM, has been officially accepted by the SEC. The filing, under File Number 333-234651, marks a significant regulatory milestone for Tracon Pharmaceuticals.
tracon pharmaceuticals公司已於2024年11月1日收到美國證券交易所(SEC)的生效通知。 該通知表示,公司提交的文件,由訪問編號0000950170-24-119598和提交類型爲POS Am標識,已被SEC正式接受。 根據文件號碼333-234651進行的申報爲tracon pharmaceuticals標誌着一個重要的監管里程碑。
tracon pharmaceuticals公司已於2024年11月1日收到美國證券交易所(SEC)的生效通知。 該通知表示,公司提交的文件,由訪問編號0000950170-24-119598和提交類型爲POS Am標識,已被SEC正式接受。 根據文件號碼333-234651進行的申報爲tracon pharmaceuticals標誌着一個重要的監管里程碑。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息